伊伐布雷定联合七叶皂苷钠治疗老年心力衰竭合并慢性阻塞性肺疾病的临床疗效

doi:10.3969/j.issn.1671-7171.2022.03.019

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1110 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨伊伐布雷定联合七叶皂苷钠对老年心力衰竭合并慢性阻塞性肺疾病(COPD)患者的临床疗效。【方法】选取2019年3月至2020年6月西安交通大学第一附属医院收治的92例老年心力衰竭合并COPD患者,采用随机数字表法分为观察组(采用伊伐布雷定联合七叶皂苷钠治疗)和对照组(采用伊伐布雷定治疗),每组各46例。比较两组治疗前后心功能、肺功能、运动耐力,记录两组患者治疗不良反应发生情况。【结果】治疗后,两组患者左室射血分数均高于治疗前,左室舒张末期内径、左心室舒张末期容积室间隔舒张期厚度均低于治疗前,且观察组与对照组比较差异均有统计学意义(P<0.05);两组患者用力肺活量、第一秒用力呼气容积、6 min步行距离均高于治疗前(P<0.05),且观察组均高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为13.04%(6/46),高于对照组的8.70%(4/46),但差异无统计学意义(χ²=0.45,P=0.50＞0.05)。【结论】伊伐布雷定联合七叶皂苷钠治疗可明显改善老年心力衰竭并COPD患者心、肺功能,提高运动耐力,且安全性良好,具有一定临床应用价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	曾新春
	李金科

关键词 ：心力衰竭/并发症, 肺疾病, 慢性阻塞性, 心血管药物(中药), 治疗结果

Abstract：【Objective】 To investigate the clinical efficacy of ivabradine combined with sodium aescinate in elderly patients with heart failure complicated with chronic obstructive pulmonary disease (COPD). 【Methods】 A total of 92 elderly patients with heart failure complicated with COPD treated in the First Affiliated Hospital of Xi'an Jiaotong University from March 2019 to June 2020 were randomly divided into observation group (treated with ivabradine combined with sodium aescinate) and control group (treated with ivabradine), with 46 cases in each group. The cardiac function, pulmonary function and exercise endurance of the two groups were compared before and after treatment, and the adverse reactions of the two groups were recorded. 【Results】After treatment, the left ventricular ejection fraction, left ventricular end diastolic diameter, left ventricular end diastolic volume and ventricular septal diastolic thickness in the two groups were higher than those before treatment, and the difference between the observation group and the control group was statistically significant (P<0.05); The forced vital capacity, forced expiratory volume in the first second and 6-minute walking distance of the two groups were higher than those before treatment (P<0.05), and the observation group was higher than that of the control group (P<0.05). The incidence of adverse reactions in the observation group was 13.04% (6/46), higher than 8.70% (4/46) in the control group, but the difference was not statistically significant (χ²=0.45=0.45, P=0.50>0.05). 【Conclusion 】Ivabradine combined with sodium aescinate can significantly improve the heart and lung function and exercise endurance of elderly patients with heart failure and COPD, with good safety and certain clinical value.

Key words： Heart Failure/CO Pulmonary Disease, Chronic Obstructive CARDIOVASCULAR AGENTS(TCD) Treatment Outcome

收稿日期: 2021-09-02

中图分类号:

R541.61

通讯作者: * E-mail:2678828444@qq.com

引用本文:

曾新春, 李金科. 伊伐布雷定联合七叶皂苷钠治疗老年心力衰竭合并慢性阻塞性肺疾病的临床疗效[J]. 医学临床研究, 2022, 39(3): 390-392.
ZENG Xin-chun, LI Jin-ke. Clinical Efficacy of Ivabradine Combined with Sodium Aescinate in the Treatment of Senile Heart Failure Complicated with Chronic Obstructive Pulmonary Disease. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 390-392.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.03.019 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I3/390